Clifford Chance advised Zak?ady Farmaceutyczne “Polpharma” S.A. on the deal, while Norton Rose Fulbright advised a consortium of financial institutions.The transaction involved a term and revolving facility…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
